You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
A randomised feasibility study of EPA and Cox-2 inhibitor (Celebrex) versus EPA, Cox-2 inhibitor (Celebrex), Resistance Training followed by ingestion of essential amino acids high in leucine in NSCLC cachectic patients - ACCeRT Study
|
|---|---|
| Published in |
BMC Cancer, November 2011
|
| DOI | 10.1186/1471-2407-11-493 |
| Pubmed ID | |
| Authors |
Elaine S Rogers, Roderick D MacLeod, Joanna Stewart, Stephen P Bird, Justin WL Keogh |
| Abstract |
Cancer cachexia is a syndrome of progressive weight loss. Non-small cell lung cancer patients experience a high incidence of cachexia of 61%. Research into methods to combat cancer cachexia in various tumour sites has recently progressed to the combination of agents.The combination of the anti-cachectic agent Eicosapentaenoic acid (EPA) and the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib has been tested in a small study with some benefit. The use of progressive resistance training (PRT) followed by the oral ingestion of essential amino acids (EAA), have shown to be anabolic on skeletal muscle and acceptable in older adults and other cancer groups.The aim of this feasibility study is to evaluate whether a multi-targeted approach encompassing a resistance training and nutritional supplementation element is acceptable for lung cancer patients experiencing cancer cachexia. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 161 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| United Kingdom | 1 | <1% |
| India | 1 | <1% |
| Canada | 1 | <1% |
| Unknown | 156 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 27 | 17% |
| Student > Bachelor | 24 | 15% |
| Researcher | 18 | 11% |
| Student > Ph. D. Student | 17 | 11% |
| Student > Doctoral Student | 10 | 6% |
| Other | 33 | 20% |
| Unknown | 32 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 45 | 28% |
| Nursing and Health Professions | 28 | 17% |
| Agricultural and Biological Sciences | 15 | 9% |
| Sports and Recreations | 14 | 9% |
| Biochemistry, Genetics and Molecular Biology | 4 | 2% |
| Other | 14 | 9% |
| Unknown | 41 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 December 2011.
All research outputs
#18,301,870
of 22,659,164 outputs
Outputs from BMC Cancer
#5,416
of 8,238 outputs
Outputs of similar age
#195,452
of 239,459 outputs
Outputs of similar age from BMC Cancer
#66
of 92 outputs
Altmetric has tracked 22,659,164 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 8,238 research outputs from this source. They receive a mean Attention Score of 4.3. This one is in the 21st percentile – i.e., 21% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 239,459 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 92 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.